Valbiotis obtains patent for its active substance TOTUM-63 in China.

Valbiotis has obtained a patent in China for TOTUM-63. This patent protects is issued by the China National Intellectual Property Administration (CNIPA), and protects the composition and use of TOTUM-63 for the prevention of type 2 diabetes and metabolic diseases until 2035.

China, whose economic development has been accompanied by an explosion of metabolic disorders since the 2000s, is now believed to have the largest prediabetic population in the world, with an estimated 390 million people (35% of the adult population).

Valbiotis is achieving its global protection strategy, with the TOTUM-63 patent now acquired in nearly 50 countries including Europe, the United States and China, to market this active substance worldwide in partnership with Nestlé Health Science.

VALBIOTIS
Biopôle Clermont-Limagne
Phone. +33 546 284 567
Contact: Marc Delaunay | marc.delaunay@valbiotis.com